Inhaled<unk>  belongs to a group of drugs called beta-2 agonists. These drugs stimulate beta-2 receptors present in the bronchial musculature. This causes them to relax and prevent the onset and worsening of symptoms of asthma. They act on the enzyme adenyl cyclase which increases the concentration of cAMP (Cyclic adenosine monophosphate). This cyclic AMP decreases the<unk> ooth muscle tone. This drug is 10,000-times more lipid soluble than the short acting beta-2 adrenoceptor agonist, albuterol. Unlike albuterol,<unk>  becomes dissolved in the lipid bilayer of the cell membrane, and its gradual dissociation from the cell membrane provides beta-2 adrenoceptors with a supply of agonist for an extended period of time. The primary noticeable difference of<unk>  from<unk> butamol, and other short-acting β2 adrenoreceptor agonists (SABAs), is its duration of action.<unk>  lasts approximately 12 hours in comparison with<unk> butamol, which lasts about 4–6 hours. When used regularly every day as prescribed, inhaled<unk>  decreases the number and severity of asthma attacks. Formoterol has been demonstrated to have a faster onset of action than<unk>  as a result of a lower lipophilicity, and has also been demonstrated to be more potent—a 12 µg dose of formoterol has been demonstrated to be equivalent to a 50 µg dose of<unk> .
Salmeterol
Fluticasone
Formoterol
Flumetasone
Arformoterol
Clobetasone
Levosalbutamol
Fluticasone propionate